10 results about "Glucose stimulation" patented technology

The invention relates to the technical field of biology, in particular to application of SAFit2 in preparation of a reagent for improving pancreas islet dysfunction. The invention discovers that SAFit2 has a remarkable improvement effect on insulin secretion dysfunction in a high-glucose and high-fat induced islet injury model. Experiments show that in a high glucose (33 mM) combined palmitic acid (500 [mu] M) injury model, the SAFit2 can significantly improve the insulin secretion function of the pancreas islet. Specifically, the SAFit2 is pretreated, the glucose stimulated insulin secretion (GSIS) index of the pancreas islet and the intracellular insulin content are remarkably increased, insulin secretion under high glucose stimulation is promoted, and the SAFit2 is proved to have the effect of promoting the insulin secretion function of the pancreas islet beta cells.

The invention relates to the technical field of biological medicines, in particular to a miR-23a-5p cavernous body, a cavernous adeno-associated virus, a preparation method of the miR-23a-5p cavernous body and the cavernous adeno-associated virus and application of the miR-23a-5p cavernous body and the cavernous The invention provides a miR-23a-5p cavernous body, and the nucleotide sequence of the miR-23a-5p cavernous body is as shown in SEQ ID NO. 1. The miR-23a-5p cavernous body and the miR-23a-5p cavernous adeno-associated virus prepared from the miR-23a-5p cavernous body can effectively relieve insulin secretion function damage caused by islet glucose stimulation and peripheral tissue insulin resistance caused by high-fat feeding, and can be used as a miR-23a-5p inhibitor to inhibit miR-23a-5p expression in adipose tissues, improve insulin resistance and inhibit the growth of the adipose tissues. And occurrence and development of type 2 diabetes mellitus are controlled.

The invention relates to the field of biology, in particular to application of tauroursodeoxycholic acid in preparation of a medicine for promoting function maturation of islet organs. The specific effect of tauroursodeoxycholic acid in promoting functional maturation of iPSC-derived islet-like organs is found and verified for the first time, and a brand new treatment thought is represented. The beta cell functional gene expression and glucose stimulation response capability of the sc-islet can be remarkably improved only by performing TUDCA treatment for 96 hours, and the function maturation period is greatly shortened. The obvious effect can be achieved by adopting the low-dose TUDCA with the concentration of 25-100 ng / mL, the cost is reduced, and the potential toxicity risk is reduced. Key indexes (functional gene expression and glucose response) of beta cell maturation are directly targeted, and a high-quality cell model is provided for research and treatment of diabetes mellitus.

The present application provides a kind of active glycopeptide of Hericium erinaceus with liver protection, blood sugar reduction and immune activity and its preparation method and application, belong to edible fungus processing technical field.The present application provides an active glycopeptide of Hericium erinaceus, the amino acid sequence of the active glycopeptide of Hericium erinaceus is as shown in SEQ ID NO:1;The Thr site of the active glycopeptide of Hericium erinaceus is connected by O-connection mode with the oligosaccharide chain consisting of 7 mannose residues.The active glycopeptide of Hericium erinaceus of the present application can promote cell consumption glucose, stimulate macrophage cell production NO, and can relieve hydrogen peroxide induced liver injury.Animal model experiment of the present application shows that the active glycopeptide of Hericium erinaceus can effectively reduce fasting blood sugar level, regulate the tolerance of organism to glucose, and can relieve liver inflammatory response, improve fat metabolism in liver.

The invention belongs to the technical field of drug synthesis, and relates to a quinolinone derivative which is a compound with a structure shown in a general formula (I) and an isomer or pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof, and is used for preparing drugs for treating and / or preventing diabetes-related diseases. The compound plays a role by promoting glucose consumption of an organism, and can promote glucose consumption of HepG2 hepatocytes and 3T3-L1 adipocytes in vitro; in an in-vivo experiment, after intragastric administration of the compound, the blood glucose level of a normal C57BL / 6j mouse after glucose stimulation is reduced in a dose-dependent manner; the fasting blood glucose, the random blood glucose, the food intake and the water intake of db / db diabetes model mice are reduced in a dose-dependent manner, the glucose tolerance of the db / db mice is improved, and the protective effect on the liver function is displayed.

A method to enhance beta-islet function and survival for treatments of diabetes by targeting PRKAR2B, and a method of preparing genetically modified human pluripotent stem cell (hPSC) in vitro, comprising providing hPSCs, with said modification comprising reducing or eliminating the expression or function of the gene products of the PRKAR2B gene in said hPSCs to be capable of differentiating in vitro to give rise to beta islets with enhanced function in glucose-stimulated insulin secretion and cell survival,are provided.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a culture medium for inducing mesenchymal cells to differentiate into insulin-secreting cells and application of the culture medium. By accurately regulating and controlling the oxidation-reduction state of NAD < + > / NADH in cells, the composition proportion of exogenous fatty acid, the dynamic supply concentration of glucose and the anti-oxidative stress level, the differentiation efficiency is remarkably improved, the induction period is shortened, and the method is suitable for industrial production on the premise of not depending on recombinant protein induction factors such as Activin A and Wnt3a. And a mature beta-like cell with stable glucose stimulus dependent insulin secretion (GSIS) capability is obtained. The kit is especially suitable for human adipose tissue-derived mesenchymal stem cells, and can be used as an independent kit product for preclinical research and drug screening of diabetes cell replacement therapy.

The application relates to the technical field of biological pharmacy, in particular to application of recombinant protein DEL-1 in preparation of a drug for improving insulin secretion function of human islets. The application finds that the recombinant protein DEL-1 has a significant improvement effect on insulin secretion dysfunction in various human islet injury models. Experiments show that in a high-sugar combined palmitic acid injury model and an inflammatory cytokine injury model, DEL-1 can significantly improve the insulin secretion function of human islets. Specifically, compared with an injury group, after DEL-1 treatment, the glucose stimulation index of human islets and the relative secretion amount of insulin under high-sugar stimulation are both significantly increased, which proves that DEL-1 has a clear effect of promoting insulin secretion function of human islet beta cells.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a method for inducing mesenchymal stem cells to differentiate into insulin-secreting cells and application of the method. According to the method, a culture system is regulated and controlled by stages, the glucose concentration is respectively regulated in different induction stages, an NAD + precursor substance, a fatty acid composition and an antioxidant factor are added, and a three-dimensional microcarrier culture mode is combined, so that the cell metabolism state, the oxidation-reduction balance and the space structure are dynamically regulated and controlled. Under the condition of not depending on recombinant protein inducing factors such as Activin A and Wnt3a, the efficient directional differentiation of the mesenchymal stem cells to the insulin-secreting cells is realized. By adopting the method disclosed by the invention, the differentiation efficiency can be improved, the induction period can be shortened, the mature beta-like cells with a stable glucose stimulation dependent insulin secretion function can be obtained, and the method is suitable for induced differentiation and related research application of the human adipose-derived mesenchymal stem cells.

The invention relates to the technical field of biology, and particularly discloses application of deferoxamine and deferiprone in preparation of a biological agent for relieving or preventing hypoxia injury in pancreas islet in-vitro culture. Through combined treatment of deferoxamine and deferoxone, the accumulation amount of Fe < 2 + > and the accumulation amount of a lipid peroxidation product 4-HNE of in-vitro cultured pancreas islet are remarkably reduced, the situation that insulin secretion GSIS is remarkably weakened due to glucose stimulation is remarkably improved, and finally hypoxia injury is reduced.